A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)Petr Krivorotko, Alexey Manikhas, Tomasz Sarosiek et al.|Annals of Oncology|2018Cited by 0
64857 The impact of continuous secukinumab treatment through week 104 on efficacy outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, D. Ioannides et al.|Journal of the American Academy of Dermatology|2025Cited by 0